Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

335
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
335
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

357
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
357
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

256
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
256
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

349
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
349
Assessment of the Rectum and Anus01:25

Assessment of the Rectum and Anus

465
Evaluating the rectum and anus plays a crucial role in conducting a thorough physical examination of the gastrointestinal system. Although it may be uncomfortable and often embarrassing for the patient, it holds immense diagnostic value, particularly in detecting gastrointestinal diseases and abnormalities. This guide will explain how to perform this assessment using inspection and palpation methods.
Rectal Inspection
Begin by inspecting the perianal and anal areas for color, texture, rashes,...
465
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

347
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Organ preservation in rectal cancer following clinical complete response after short-course radiotherapy-based total neoadjuvant therapy.

Clinical and translational radiation oncology·2026
Same author

Moving beyond anatomy: the future of rectal cancer management is biologically-informed, response-adapted, and patient-centered.

Clinical and translational radiation oncology·2026
Same author

DUAL CROSS-ATTENTION SIAMESE TRANSFORMER FOR RECTAL TUMOR REGROWTH ASSESSMENT IN WATCH-AND-WAIT ENDOSCOPY.

Proceedings. IEEE International Symposium on Biomedical Imaging·2026
Same author

Impact of Dedicated Care Coordination on Access to Multidimensional Support Services in Young-Onset Colorectal Cancer: A Pragmatic Trial.

JCO oncology practice·2026
Same author

Integrating real-time patient-reported outcomes in colorectal cancer care: development and evaluation of a concise clinical scorecard.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation·2026
Same author

Ensuring High-Quality Rectal Cancer Surgery in an Era of Increasing Treatment Complexity.

Annals of surgical oncology·2026

Related Experiment Video

Updated: Sep 28, 2025

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

5.9K

Neoadjuvant Therapy for Rectal Cancer.

Felipe F Quezada-Diaz1, J Joshua Smith2

  • 1Colorectal Unit, Department of Surgery, Complejo Asistencial Doctor Sótero del Río, Avenida Concha y Toro#3459, Santiago, Puente Alto, RM 8207257, Chile. Electronic address: https://twitter.com/ffquezad.

Surgical Oncology Clinics of North America
|March 30, 2022
PubMed
Summary

Neoadjuvant treatment for rectal cancer improves local control but not survival. This review explores optimal neoadjuvant strategies, their benefits, toxicities, and novel approaches for locally advanced rectal cancer.

Keywords:
ChemoradiationNeoadjuvant therapyRectal cancerShort-course radiotherapyTotal neoadjuvant therapy

More Related Videos

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

30.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

633

Related Experiment Videos

Last Updated: Sep 28, 2025

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
12:45

Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer

Published on: February 12, 2022

5.9K
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

30.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

633

Area of Science:

  • Oncology
  • Gastroenterology
  • Surgical Oncology

Background:

  • Locally advanced rectal cancer (LARC) treatment is complex, necessitating a multidisciplinary team.
  • Neoadjuvant therapy, combining radiotherapy, chemotherapy, and surgery, enhances local tumor control.
  • Current neoadjuvant strategies for LARC lack proven overall survival benefits and cause significant toxicities, impacting patient quality of life.

Purpose of the Study:

  • To review current neoadjuvant treatment regimens for LARC.
  • To analyze the benefits and toxicities associated with each neoadjuvant strategy.
  • To explore novel and emerging approaches in neoadjuvant rectal cancer therapy.

Main Methods:

  • Literature review of neoadjuvant treatment strategies for LARC.
  • Analysis of clinical trial data on efficacy, toxicity, and quality of life outcomes.
  • Discussion of evolving treatment paradigms and future research directions.

Main Results:

  • Neoadjuvant treatment improves local control in LARC but has not demonstrated a significant increase in overall survival.
  • Established neoadjuvant regimens are linked to considerable toxicities and long-term side effects.
  • The optimal neoadjuvant strategy for LARC remains an area of active investigation.

Conclusions:

  • Optimizing neoadjuvant treatment for LARC is crucial for improving patient outcomes and quality of life.
  • Balancing treatment efficacy with toxicity is a key challenge in current neoadjuvant rectal cancer management.
  • Further research into novel neoadjuvant approaches is warranted to enhance survival and minimize long-term sequelae.